Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback